Leronlimab- Vyrologix is a humanized monoclonal antibody drug used to treat HIV patients. The drug is a C-C chemokine receptor type 5 (CCR5) antagonist that protects healthy T cells from viral infection. The CCR5 receptor plays a crucial role in modulating immune cell trafficking to sites of inflammation. Because of the drug’s ability to mitigate the cytokine storm which is common in COVID-19 fatalities, it has become the basis for its study as a potential COVID-19 treatment.
Leronlimab- Vyrologix appears to be a powerful treatment with hardly any drug related serious adverse events. CytoDyn’s recent treatment of patients under eIND (Emergency Investigational New Drug) with leronlimab for COVID-19 infection have shown impressive results as the drug reduced the plasma viral load and restored the immune function by day 7.5,
